Abstract:Background and Aims: A cohort of patients with inflammatory bowel disease (IBD) exhibit expansion of the gut pathobiont, adherent invasive (AIEC). Loss of activity of the IBD susceptibility gene, protein tyrosine phosphatase type 2 (PTPN2), results in dysbiosis of the gut microbiota both in human subjects and mice. Further, constitutive knock-out ( –KO) mice display expansion of AIEC compared to wildtype littermates. CEACAM6, a host cell surface glycoprotein, is exploited by AIEC to attach to and enter intestinal epithelial cells (IECs). Here, we investigate the role of IEC-specific PTPN2 in restricting AIEC invasion. Methods: Biopsies from IBD patients heterozygous (CT) or homozygous (CC) for the SNP (single nucleotide polymorphism) rs1893217 were processed for immunohistochemistry. HT29 intestinal epithelial cells (IEC) were transfected with control shRNA (PTPN2–CTL), or a shRNA targeted towards PTPN2 (PTPN2–KD). The rs1893217 SNP was inserted (PTPN2–KI), or a complete knock-out of PTPN2 (PTPN2–KO) was generated, with CRISPR-Cas9 gene editing of Caco-2BBe IEC lines. Adherence and invasion assays were performed with either the human IBD AIEC isolate, LF82, or a novel fluorescent-tagged mouse adherent invasive (mAIEC ) at multiplicity of infection (MOI) of 10. IL–6 and the pan–JAK inhibitor tofacitinib were administered to interrogate JAK–STAT signaling. Protein expression was determined by western blotting and densitometry. Results: CEACAM6 expression was elevated (colon and ileum) in IBD patients carrying the rs1893217 SNP (CT, CC) compared to wildtype (TT) IBD patients. HT29 and Caco-2BBe cell lines deficient in PTPN2 expressed significantly higher levels of CEACAM6. Further, PTPN2–KI and PTPN2–KO cell lines also displayed greater adherence and invasion by AIEC LF82 and higher mAIEC invasion. CEACAM6 expression was further elevated after administration of IL–6 in PTPN2–deficient cell lines compared to untreated controls. Silencing of STAT1 and 3 partially reduced CEACAM6 protein expression. Tofacitinib significantly reduced the elevated CEACAM6 protein expression and the higher AIEC adherence and invasion in PTPN2–KI and PTPN2–KO cell lines compared to DMSO controls. Conclusion: Our findings highlight a crucial role for PTPN2 in restricting pathobiont entry into host cells. Our study also describes a role for the FDA-approved drug, tofacitinib (Xeljanz) in correcting the JAK–STAT–mediated overexpression of CEACAM6, used by pathobionts as an entry portal into host cells. These findings suggest a role for JAK-inhibitors in mitigating AIEC colonization in IBD susceptible hosts.

Inhibition of CEACAM1 expression in cytokine-activated neutrophils using JAK inhibitors

S-nitrosocaptopril Interrupts Adhesion of Cancer Cells to Vascular Endothelium by Suppressing Cell Adhesion Molecules Via Inhibition of the NF-кB and JAK/STAT Signal Pathways in Endothelial Cells

Effects of antioxidants and NO on TNF-α-induced adhesion molecule expression in human pulmonary microvascular endothelial cells

Carcinoembryonic antigen-related cell adhesion molecule 1 down regulates Syk coupled neutrophil NLRP3 inflammasome activation through ITIM and the recruitment of SHP-1 (157.12)

Effects of CEACAM1 in oral keratinocytes on HO-1 expression induced by Candida β-glucan particles

The JAK inhibitor, Tofacitinib, Corrects the Overexpression of CEACAM6 and Limits Susceptibility to AIEC Caused by Reduced Activity of the IBD Associated Gene, PTPN2

Elevation of Neutrophil Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Associated with Multiple Inflammatory Mediators Was Related to Different Clinical Stages in Ischemic Stroke Patients

Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production

Discordant effects of Janus kinases inhibition ex-vivo on inflammatory responses in colonic compared to ileal mucosa

Neutrophil elastase inhibitor suppresses IL-17 based inflammation of murine experimental colitis

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

CEACAM1 Inhibited IB-/NF-B Signal Pathway Via Targeting MMP-9/TIMP-1 Axis in Diabetic Atherosclerosis

Effect of PD98059, a Selective MAPK3/MAPK1 Inhibitor, on Acute Lung Injury in Mice

CEACAM1-engineered MSCs have a broad spectrum of immunomodulatory functions and therapeutic potential via cell-to-cell interaction

Cathepsin C inhibition reduces neutrophil serine protease activity and improves activated neutrophil-mediated disorders

Chemical JAK inhibitors for the treatment of rheumatoid arthritis

Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

CEACAM1 Inhibited IκB-α/NF-κB Signal Pathway Via Targeting MMP-9/TIMP-1 Axis in Diabetic Atherosclerosis

Neutrophil CEACAM1 determines susceptibility to NETosis by regulating the S1PR2/S1PR3 axis in liver transplantation

CEACAM expression in an in-vitro prostatitis model